Eflornithine-HCl (α-difluoromethylornithine or DFMO), an irreversible inhibitor of ornithine decarboxylase, blocks polyamine synthesis and has demonstrated antitumor activity in cell culture and animal tumor models. This phase I study was designed to determine and compare toxicity and the maximally tolerated dose of a 4-day course of DFMO given to patients in oral, continuous intravenous infusion or pulse intravenous infusion forms. Twenty-four patients were entered into this study: 8 received intravenous pulse drug, 10 intravenous continuous infusion of drug, and 6 oral DFMO. The most frequent toxicity was nausea and vomiting which occurred in 9 courses of oral drug. Only two patients receiving intravenous DFMO had nausea and vomiting. Clinically significant thrombocytopenia and audiometric abnormalities were not encountered in contrast to previous experience with 28-day courses of oral DFMO. The maximally tolerated dose of a four-day course of oral DFMO was 3.75 gm/M2 every 6 hours. The maximally tolerated dose of intravenous pulse and continuous infusion DFMO was not attained. Pharmacokinetic studies demonstrated that the intravenous schedules achieved higher plasma levels of DFMO than those previously obtained with chronic oral dosing.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Sjoerdsma A, Schechter PJ: Chemotherapeutic implications of polyamine biosynthesis inhibition. Clin Pharmacol Ther 35:287–300, 1984
Metcalf R, Bey P, Danzin C, Jung MJ, Cassara P, Vevert JP: Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C. 126.96.36.199) by substrate and product analogues. J Am Chem Soc 100:2551–2553, 1978
Pegg AE, McCann PP: Polyamine metabolism and function. Am J Physiol 243:C212-C221, 1982
Mamont PS, Dechesne MC, Grove J, Bey P: Antiproliferative properties of DL-α-difluoromethylornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun 81:58–66, 1978
Prakash NJ, Schechter PJ, Grove J, Koch-Weser J: Effect of alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase on L1210 leukemia in mice. Cancer Res 38:3059–3062, 1978
Prakash NJ, Schechter PH, Mamont PS, Grove J, Koch-Weser J, Sjoerdsma A: Inhibition of EMT 6 tumor growth by interference with polyamine biosynthesis; effects of alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase. Life Sci 26:181–194, 1980
Bartholeyns J: Treatment of metastatic Lewis lung carcinoma with DL-α-difluoromethylornithine. Eur J Cancer Clin Oncol 19:567–572, 1987
Luk GD, Civin CI, Weissman RM, Baylin SB: Ornithine decarboxylase: essential in proliferation but not differentiation of human promyelocytic leukemia cells. Science 216:75–77, 1982
Luk GD, Goodwin G, Marton LJ, Baylin S: Polyamines are necessary for the survival of human small-cell carcinoma in culture. Proc Natl Acad Sci USA 78:2355–2358, 1981
Sunkara PS, Fowler SR, Nishioka K, Rao PN: Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine potentiates the cytotoxic effects of arabinosyl cytosine in HeLa cells. Biochem Biophys Res Commun 95:423–430, 1980
Chang BK, Black Jr O, Gutman R: Inhibition of growth of human or hamster pancreatic cancer cell lines by α-difluoromethylornithine alone and combined with cis-diamminedichloroplatinum (11). Cancer Res 44:5100–5104, 1984
Hung DT, Deen DF, Seidenfeld J, Marton LJ: Sensitization of 9L rat brain gliosarcoma cells to 1,3,-bis (2-chloroethyl)-1-nitrosourea by α-difluoromethylornithine, an ornithine decarboxylase inhibitor. Cancer Res 41:2783–2785, 1981
Bartholeyns J, Koch-Weser J: Effects of α-difluoromethylornithine alone and combined with Adriamycin and vindesine on L1210 leukemia in mice, EMT 6 solid tumors in mice, and solid tumors induced by injection of hepatoma tissue culture cells in rats. Cancer Res 41:5158–5161, 1981
Talpaz M, Quesada J, Gutterman JU: Phase I study of difluoromethylornithine (DFMO) and leukocyte interferon (INF) in cancer patients (Abstract). Proc Am Soc Clin Oncol 3:246, 1984
Abeloff MD, Slavik M, Luk GD, Griffin CA, Hermann J, Blanc O, Sjoerdsma A, Baylin S: Phase I trial and pharmacokinetic studies of α-difluoromethylornithine — an inhibitor of polyamine biosynthesis. J Clin Oncol 2:124–130, 1984
Abeloff M, Rosen S, Luk G, Baylin S, Zeltzman M, Sjoerdsma A: Phase II trials of α-difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, in advanced small cell lung cancer (SCLC) and colon cancer (CC) (Abstract). Proc Am Soc Clin Oncol 4:705, 1985
Haegele KD, Alken RG, Grove J, Schechter PJ, Koch-Weser J: Kinetics of α-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin Pharmacol Ther 30:210–217, 1981
Grove J, Fozard JR, Mamont PS: Assay of α-difluoromethylornithine in body fluids and tissues by automatic amino acid analysis. J Chromatogr 223: 409–416, 1981
Slavik M, Mayfield A, Wood A, Blanc O: Pharmacokinetic studies with α-difluoromethylornithine (αDFMO) (Abstract). Proc Am Assoc Cancer Res 23:203, 1982
Gibaldi M, Perrier D: Pharmacokinetics. New York, Marcel Dekker, 1975, pp. 281–292
Ritschell WA: Handbook of Basic Pharmacokinetics. Hamilton, Illinois, Drug Intelligence Publications, Inc., 1980, p. 293
Luk GD, Sharkis SJ, Abeloff MD, McCann PP, Sjoerdsma A, Baylin SB: Polyamine biosynthesis is required for the maintenance of peripheral blood elements in the rat. Proc Natl Acad Sci USA 80:5090–5093, 1983
Golden JA, Sjoerdsma A, Santi DV: Pneumocystis carinii pneumonia treated with α-difluoromethylornithine. West J Med 141:613–623, 1984
Luk GD, Abeloff MD, Griffin CA, Baylin SB: Successful treatment with DL-α-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice. Cancer Res 43:4239–4243, 1983
About this article
Cite this article
Griffin, C.A., Slavik, M., Chien, S.C. et al. Phase I trial and pharmacokinetic study of intravenous and oral α-Difluoromethylornithine. Invest New Drugs 5, 177–186 (1987). https://doi.org/10.1007/BF00203544
- phase I study